# Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement

Study · id `cardio:ct-nct03284827` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03284827](<https://clinicaltrials.gov/study/NCT03284827>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03284827

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 235 participants.

## Technical summary

Registry record NCT03284827. Randomized; no masking; primary purpose prevention. Start 2018-03-15 (actual); primary completion 2021-10-26 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 235 participants (enrolled count; ClinicalTrials.gov record NCT03284827, source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)
- Started: 2018-03-15 (actual) (ClinicalTrials.gov record NCT03284827, source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)
- Primary completion: 2021-10-26 (actual) (ClinicalTrials.gov record NCT03284827, source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)
- Completion: 2021-11-05 (actual) (ClinicalTrials.gov record NCT03284827, source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)
- Countries: Hong Kong SAR China; South Korea; Taiwan (ClinicalTrials.gov record NCT03284827, source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03284827-2021-11-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
- Acronym: ADAPT-TAVR
- Condition: Aortic Valve Stenosis
- Intervention (Drug): NOAC
- Intervention (Drug): DAPT
- Lead sponsor: Duk-Woo Park, MD
- Lead sponsor class: OTHER
- Collaborator: CardioVascular Research Foundation, Korea
- Collaborator class: OTHER
- Collaborator: Daiichi Sankyo Korea Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry lists this organization as the lead sponsor: Duk-Woo Park, MD (`cardio:org-duk-woo-park-md`)
- Registry lists this organization as a collaborator: CardioVascular Research Foundation, Korea (`cardio:org-cardiovascular-research-foundation-korea`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial (`cardio:pubmed-35373583`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement (`cardio:pubmed-37586823`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: baf2ef8576a9c0e28533718c9ce8781d40df2057a45151a93a6ab1d5a4c21261
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
